NCT03093116 2026-05-27TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA
NCT05489237 2026-05-04First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal TumorsIDRX, Inc., a wholly owned subsidiary of GSK, LLCPhase 1 Recruiting278 enrolled